Awad S, Al-Ahmer SD, Salih SM

Language: English
References: 20
Page: 136-142
PDF size: 812.44 Kb.

ABSTRACT

Cholera is endemic in over 50 countries with an estimated mortality of 100,000-120,000. Vaccination is considered the complementary key to prevent and control cholera; therefore, alternative vaccine preparations are needed. Toxin Co-regulated Pilus is part of the toxR virulence regulon, which is necessary for colonization in the intestinal mucosa. In order to express Vibrio cholerae TcpA protein in Saccharomyces boulardii, the expression plasmid pYES2 was constructed by inserting tcpA gene isolated from local Vibrio cholerae Eltor Inaba isolates. The new construct was transferred into Saccharomyces boulardii cells and the expression of tcpA gene was induced from the GAL1 promoter by adding galactose to the medium. The SDS-PAGE and Western blot analysis showed the presence of TcpA in yeast. These results showed that Saccharomyces boulardii is a promising host to express Vibrio cholerae toxin TcpA as the first step in attempt to produce an oral Vibrio cholerae vaccine.

REFERENCES

1. World Health Organization [Internet]. Ginebra: WHO; 2019. Newsroom. Fact-sheets. Cholera. Available form: https://www.who.int/news-room/fact-sheets/detail/cholera. (Accessed online: January 17,2019).

2. Health cluster Iraq. Wash cluster. Iraq Health and WASH Cluster Acute Diarrheal Disease (including Cholera) Preparedness and Response Plan [Internet]. New York; 2018. Available form: https://reliefweb.int/report/iraq/iraq-health-and-wash-cluster-acute-diarrheal-disease-including-cholera-preparedness-and. (Accessed online: December 26,2018).

3. Benenson AS, Joseph PR, Oseasohn RO. Cholera vaccine field trials in East Pakistan: 1. Reaction and antigenicity studies. Bull World Health Organ.1968;38(3):347-57.

4. Bishop AL, Camilli A. Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccine.2011;10(1):79-94.

5. Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol.2012;5(2):111-25.

6. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a metaanalysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6:374-82.

7. Douradinha B, Reis VC, Rogers MB, Torres FA, Evans JD, Marques Jr ET. Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii. Bioengineered.2014; 5(1):21-9.

8. Vohra A, Satyanarayana T. Probiotic yeasts. In: Satyanarayana T, Johri BN, Prakash A, editors. Microorganisms in sustainable agriculture and biotechnology. Dordrecht: Springer; 2012.p. 411-33

9. Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, et al. Metabolic engineering of probiotic Saccharomyces boulardii. Appl Environ Microbiol.2016; 82:2280-7.doi:10.1128/AEM.00057-16.

10. Khatri I, Tomar R, Ganesan K, Prasad GS, Subramanian S. Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii. Sci Rep. 2017; 7(1):371.doi:10.1038/s41598-017-00414-2.

11. Krebs SJ, Taylor RK. Protection and attachment of Vibrio cholerae mediated by the toxin-coregulated pilus in the infant mouse model. J. Bacteriol. 2011; 193(19):5260-70.

12. Forbes BA, Sahm DF, Weissfeld AS. Study guide for Bailey & Scott’s diagnostic microbiology. Saint Louis: Elsevier Mosby;2007.

13. Kaysner CA, DePaola A, Jones J. Bacteriological Analytical Manual (BAM) Chapter 9: Vibrio. FDA;2004. Available form: https://www.fda.gov/food/laboratory-methods-food/bam-chapter-9-vibrio.

14. Goforth JB, Walter NE, Karatan E. Effects of polyamines on Vibrio cholerae virulence properties. PLoS One.2013; 8(4):e60765.doi:10.1371/journal.pone.0060765.

15. Hudson LE, Fasken MB, McDermott CD, McBride SM, Kuiper EG, Guiliano DB, et al. Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii. PloS One.2014;9(11):e112660. doi:10.1371/journal.pone.0112660.

16. Benatuil L, Perez JM, Belk J, Hsieh CM. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel. 2010; 23(4):155-9.

17. Sambrook J, Russell DW. Molecular cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory Press; 2001.

18. Mahmood T, Yang PC. Western blot: technique, theory, and trouble shooting. N Am J Med Sci.2012;4:429-34.doi:10.4103/1947-2714.100998.

19. Lim JG, Jin HS. Heterologous expression of cholera toxin B subunit in Saccharomyces cerevisiae. Biotechnol Bioprocess E. 2008; 13:598-605.

20. Bagherpour G, Ghasemi H, Zand B, Zarei N, Roohvand F, Ardakani EM, et al. Oral administration of recombinant Saccharomyces boulardii expressing ovalbumin-CPE fusion protein induces antibody response in mice. Front microbiol. 2018; 9:723.doi:10.3389/fmicb.2018.00723.